PLAVIX 75 mg, film-coated tablets, box of 30

 

Active ingredient

Clopidogrel

 

PLAVIX is usually prescribed for:

Myocardial infarction (from a few days to less than 35 days)

Ischemic stroke (more than 7 days old and less than 6 months old)

Obliterating arteriopathy of the lower limbs

Unstable angina or non-Q-wave myocardial infarction

Acute myocardial infarction with ST-segment elevation

Prevention of atherothrombotic accident in the event of atrial fibrillation

Prevention of thromboembolic accident in the event of atrial fibrillation

PLAVIX- Indications

Secondary prevention of atherothrombotic events

Clopidogrel is indicated:

in adult patients with myocardial infarction (from a few days to less than 35 days), ischemic stroke (from more than 7 days and less than 6 months) or obliterative arterial disease lower limbs established.

in adult patients with acute coronary syndrome:

Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing coronary angioplasty with stenting, in combination with acetylsalicylic acid (ASA).

Acute ST-segment elevation myocardial infarction in combination with ASA in medically treated patients eligible for thrombolytic therapy.

Prevention of atherothrombotic and thromboembolic events in atrial fibrillation In adult patients with atrial fibrillation, who have at least one risk factor for vascular events, who cannot be treated with a vitamin K antagonist (VKA) and who are at low risk bleeding, clopidogrel is indicated, in combination with ASA, for the prevention of atherothrombotic and thromboembolic events, including stroke.

For more information see section Pharmacodynamic properties.